Merck & Co., Inc.

  • 3 Basic Reasons Medical Marijuana Stocks Are Doomed For Failure

    By Nickey Friedman - August 31, 2013 | Tickers: BMY, MDBX, MJNA, MRK, MYL, PFE

    We've all seen it. Medical marijuana stocks are flying into the stratosphere as a new industry in America is born. What's not to get excited about? There are only a handful of public companies breaking into this new, multi-billion dollar industry with high hopes and expectations of giant windfalls in profits for all. As this article explains, nobody needs to sell the industry -- it sells itself! It sells more »

  • Positive News for This Troubled Pharma Player

    By Brandy Betz - August 15, 2013 | Tickers: LLY, MRK, SNY

    Eli Lilly (NYSE: LLY) closed last Tuesday up nearly 3% following positive phase 3 results for cancer drug necitumumab. The company had previously halted a different necitumumab trial for safety issues. This positive bit of news was particularly welcome in the wake of Lilly's late-stage pipeline crashes. And with two blockbuster drugs set to expire in the next year, Eli Lilly needs all the signs of strength it can more »

  • An All-In Bet on a Game-Changing Diabetes Treatment

    By Leo Sun - August 14, 2013 | Tickers: JNJ, MNKD, MRK, PFE

    Note: This article has been amended to correct the spelling of Afrezza. Motley Fool apologizes for the error.

    In the biotech industry, there are generally two kinds of companies -- those that have established top and bottom line growth from approved products, and those that have pipelines of experimental treatments with a high potential for growth. Conservative investors favor the former, which include well-known companies like Pfizer (NYSE: PFE), Merck (NYSE: MRKmore »)

  • Gilead Races against Competitors for an Oral Hepatitis C Cure

    By Todd Campbell - August 13, 2013 | Tickers: ABBV, GILD, MRK, VRTX

    The search for a hepatitis C cure is one of the most active areas within biotechnology research and development.

    One of the company's ushering in the next generation of hepatitis C treatment is Gilead Pharmaceuticals (NASDAQ: GILD). The company acquired hepatitis C drug sofosbuvir in its $11.2 billion acquisition of Pharmasset back in January 2012.

    Sonosbuvir has a very good chance of beating rival drugs to the market more »

  • Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

    By Arturo Cuevas - August 12, 2013 | Tickers: GSK, MRK, SNY

    Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk more »

  • Next Leaders in Technology and Health Care

    By Declan Fallon - August 12, 2013 | Tickers: AKAM, CYBX, MRK

    Health Care and Technology stocks have offered the best reaction to earnings in the current quarter. The performance of stocks from the two sectors offer an interesting divergence between defensive health care and cyclical technology. This diversity offers good news for investors looking for the rally to continue. A time for worry is when buyers concentrate on defensive stocks at the expense of more speculative issues. However, the overall market more »

  • A Closer Look at Pfizer’s Three-Way Split

    By Leo Sun - August 7, 2013 | Tickers: ABT, ACT, MRK, PFE, TEVA

    Last week, pharma giant Pfizer (NYSE: PFE) announced that it was planning to split the company into three businesses -- a move that had been long anticipated by analysts and investors alike. Although this move streamlines the company’s core businesses’ financials, does it change anything for investors?

    Prelude to a spin-off

    In its first business segment led by Geno Germano, Pfizer intends to group immunology and metabolic treatments together with more »

  • Food Safety Concerns in China Could Fuel Zoetis’ Growth

    By Leo Sun - August 7, 2013 | Tickers: LLY, MRK, SFD, ZTS

    Zoetis (NYSE: ZTS), Pfizer’s former animal health business, has been on a roller coaster ride since its public debut in February. Pfizer spun off Zoetis in an effort to slim down its operations and boost revenue after the loss of patent exclusivity for its top selling cholesterol drug, Lipitor.

    <img alt="" src="" />

    Since then, the bulls and the bears are at odds regarding the future of Zoetis, and shares are still flat more »

  • A Closer Look at the Battle Over Cancer Treatments

    By Leo Sun - August 6, 2013 | Tickers: AMGN, INO, MRK, ONXX, PFE

    Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are struggling to avoid the upcoming patent cliff by acquiring companies with promising oncology treatments. In this article, I’ll take a look at several of the key companies to follow in this field, and what investors can expect from this fast more »

  • Beat the Taper: Part 1

    By Rupert Hargreaves - August 5, 2013 | Tickers: CROX, MRK, PSX

    With the Federal Reserve set to start tapering asset purchases in September, it is time to start looking for stocks that offer some protection from the impending market volatility.

    Unlike many market commentators, who recommend buying large companies with strong dividends and a long history of maintaining payouts, I do not believe this is the way to go. Indeed, the last time the Fed announced that it was considering tapering more »

  • An Eventful Occurrence Leads To A Significant Rise In This Company’s Stock Price

    By Naomi Warmate-Igwe - August 1, 2013 | Tickers: AHPI, MRK, STXS

    Stereotaxis Inc. (NASDAQ: STXS) is a leadingSt. Louis,Missouri based Medical Appliances & Equipment developer with various remarkable cardiology robotic instrument navigation systems to its credit. It also offers information management solutions that benefit interventional laboratories.

    This company, whose stock has been trading below the $2.00 mark for quiet some time now experienced a magical boost due to an eventful occurrence on July 29, 2013 – Its Vdrive Robotic Navigation System more »

  • Sleep War Z: A Written History of the Insomniac War

    By Leo Sun - July 31, 2013 | Tickers: MRK, SNY, VNDA

    It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not require medication. However, 10% to 15% of American adults reportedly suffer from chronic insomnia, which lasts for months at a time. Anxiety and depression are frequent causes of chronic insomnia, and currently available insomnia medications often contain some similar ingredients as more »

  • Will This Speculative Cholesterol Treatment Pay Off?

    By Leo Sun - July 30, 2013 | Tickers: AEGR, MRK, PFE

    In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC. Even though the American Heart Association states that people with high LDL levels exceeding 200 mg/dL are twice as likely to develop coronary heart disease, only half of adults in the U.S. seek treatment, often leading to premature death.

    This epidemic of high cholesterol levels across the more »

  • 3 Reasons GlaxoSmithKline Will Survive the China Scandal

    By Anjum Khan - July 29, 2013 | Tickers: GSK, JNJ, MRK

    GlaxoSmithKline (NYSE: GSK) has been accused of the violation of Chinese laws wherein the company’s key officials have used around 700 agencies and firms for increasing the sales and prices of drugs by bribing hospitals and doctors in China. The company has transferred around $489 million to these agencies. Four of the company’s executives are detained. This includes the vice president, the legal affairs director, the business development more »

  • Will Healthcare Take Care of Your Portfolio

    By Madhukar Dubey - July 29, 2013 | Tickers: JNJ, MRK, PFE

    During the past decade, healthcare has been one of the most stable and consistent performers among all industries. According to IMS, global spending on healthcare during 2011-2016 is expected to grow at a CAGR of around 6%. The volume growth in emerging markets for pharmaceutical companies and continuous uptick in medicine spending in developed countries should drive global growth.

    Here are three health-care companies ready to capitalize on growth opportunities more »

  • A Fine Act of balancing by Sanofi

    By Shalini Agrawal - July 27, 2013 | Tickers: LLY, MRK, NVO, SNY


    In the history spanning more than two centuries, Sanofi (NYSE: SNY) has undergone number of major and minor changes to reach the level of integrated healthcare leader as it is today. To achieve this, Sanofi has been quick to spot the value-enhancing growth opportunities resulting in a number of mergers and acquisitions that the company has undertaken successfully.

    The company’s product lie into 3 major segments termed as Pharmaceuticals more »

  • As Healthcare Demand Rises, So Will This Company's Profits

    By Matthew Frankel - July 26, 2013 | Tickers: MRK, NVS, PFE

    The aging population as well as the higher number of people who will receive benefits under new healthcare laws should combine to produce rising profits for a variety of companies with exposure to the sector. My favorite way to play this upcoming trend is through the drug companies, which should benefit from the significantly increased need for prescription medications that will result from the aforementioned causes. There are many good more »

  • What Does the Patent Cliff Mean for This Drugmaker?

    By Leo Sun - July 25, 2013 | Tickers: LLY, MRK, PFE

    For Eli Lilly (NYSE: LLY), history is repeating itself once again. The pharmaceutical company, which became a household name with its antidepressant Prozac in 1987, slipped in 2001 after it lost patent protection for its flagship drug. Over the following decade, Eli Lilly was unable to relive its Prozac-induced euphoria between 1987 and 2001, and shares have fallen nearly 30% over the past twelve years.

    <img alt="" src="" />

    Later this year, Eli Lilly more »

  • Is Teva Making a Comeback?

    By Lior Cohen - July 23, 2013 | Tickers: MRK, PFE, TEVA

    The recent rally in shares of Teva Pharmaceutical Industries (NYSE: TEVA) may suggest investors are regaining some confidence in this pharmaceutical manufacturer. Will Teva’s upcoming second-quarter financial report, which will come out on August 1, show signs of recovery? Will it surprise investors? Is it worth having this giant generic-drug manufacturer in your portfolio?

    Generic medicine sales are falling

    One of the biggest hits Teva has taken so far more »

  • Large Cap Stocks Are Cheaper Than They Appear

    By Ted Cooper - July 22, 2013 | Tickers: JNJ, MRK, PFE

    Uncertainty creates opportunity for long-term investors, and there is a lot of uncertainty in the healthcare sector right now. As a result, opportunistic investors should take a closer look at companies in this sector.

    Companies like Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), and Pfizer (NYSE: PFE) may be well followed, but, even so, the market sometimes underestimates their earning power. The patent cliff has created enormous uncertainty surrounding these more »

  • Page 1 of 15